Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:AGTCNASDAQ:CCCCNASDAQ:KYTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.20+6.0%$2.58$1.38▼$19.69$87.73M1.48591,164 shs481,600 shsAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/ACCCCC4 Therapeutics$1.32+4.8%$1.46$1.09▼$7.66$93.73M3.11.39 million shs1.03 million shsKYTXKyverna Therapeutics$2.63+3.1%$2.14$1.78▼$16.64$110.21M2.17421,055 shs262,044 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+5.96%-15.57%+4.92%+12.28%-78.71%AGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%CCCCC4 Therapeutics+4.76%-3.65%-16.46%-51.29%-73.55%KYTXKyverna Therapeutics+3.14%+6.48%+28.92%-7.39%-79.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.6315 of 5 stars3.11.00.04.62.71.70.6AGTCApplied Genetic Technologies0.1475 of 5 stars0.00.00.03.80.60.00.0CCCCC4 Therapeutics2.4241 of 5 stars3.32.00.00.03.71.70.6KYTXKyverna Therapeutics1.7297 of 5 stars3.61.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.17Hold$9.00181.25% UpsideAGTCApplied Genetic Technologies 0.00N/AN/AN/ACCCCC4 Therapeutics 2.50Moderate Buy$12.00809.09% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50603.42% UpsideCurrent Analyst Ratings BreakdownLatest AGTC, AGEN, CCCC, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $3.003/12/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$99.52M0.88N/AN/A($7.78) per share-0.41AGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51CCCCC4 Therapeutics$39.78M2.36N/AN/A$4.07 per share0.32KYTXKyverna Therapeutics$7.03M16.17N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$8.67N/AN/AN/A-145.89%N/A-85.68%8/14/2025 (Estimated)AGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/ACCCCC4 Therapeutics-$132.49M-$1.47N/AN/AN/A-313.35%-42.45%-27.55%8/7/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)Latest AGTC, AGEN, CCCC, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/11/2025Q4 2024AGENAgenus-$2.36-$2.04+$0.32-$2.04$30.09 million$26.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19AGTCApplied Genetic Technologies0.391.401.40CCCCC4 TherapeuticsN/A6.316.31KYTXKyverna TherapeuticsN/A10.5010.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%AGTCApplied Genetic Technologies22.05%CCCCC4 Therapeutics78.81%KYTXKyverna Therapeutics18.08%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%AGTCApplied Genetic Technologies4.10%CCCCC4 Therapeutics8.73%KYTXKyverna Therapeutics22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million22.38 millionOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableCCCCC4 Therapeutics15071.01 million64.55 millionOptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableAGTC, AGEN, CCCC, and KYTX HeadlinesRecent News About These CompaniesKyverna Therapeutics (NASDAQ:KYTX) Raised to "Buy" at HC WainwrightMay 29 at 1:15 AM | americanbankingnews.comKyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28 at 4:02 PM | prnewswire.comKyverna Therapeutics (NASDAQ:KYTX) Stock Rating Upgraded by HC WainwrightMay 28 at 8:15 AM | marketbeat.comHC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)May 27 at 5:40 PM | msn.comKyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial PositionMay 27 at 6:58 AM | tipranks.comAnalysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $18.33May 24, 2025 | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for KYTX EarningsMay 23, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Buy" by AnalystsMay 23, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of KYTX Q2 EarningsMay 23, 2025 | americanbankingnews.comFinancial Analysis: Kyverna Therapeutics (NASDAQ:KYTX) and Fresh Tracks Therapeutics (NASDAQ:FRTX)May 23, 2025 | americanbankingnews.comQ1 Earnings Forecast for KYTX Issued By HC WainwrightMay 22, 2025 | marketbeat.comSphera Funds Management LTD. Decreases Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 18, 2025 | marketbeat.comKyverna Shareholder Sues Over Kidney Therapy Trial Data Post IPOMay 16, 2025 | news.bloomberglaw.comWith 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investorsMay 16, 2025 | finance.yahoo.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 15, 2025 | globenewswire.comKyverna Therapeutics Reports Q1 2025 Progress and OutlookMay 15, 2025 | tipranks.comKyverna lays off 16% of staff as autoimmune CAR-T plans pick up paceMay 14, 2025 | fiercebiotech.comIntegral Health Asset Management LLC Acquires 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 14, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comKyverna Therapeutics (KYTX) Expected to Announce Earnings on TuesdayMay 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongDoorDash’s Uptrend Is Gaining Momentum in 2025By Thomas Hughes | May 9, 2025View DoorDash’s Uptrend Is Gaining Momentum in 2025IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthAGTC, AGEN, CCCC, and KYTX Company DescriptionsAgenus NASDAQ:AGEN$3.20 +0.18 (+5.96%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$3.19 -0.01 (-0.31%) As of 05/29/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Applied Genetic Technologies NASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.C4 Therapeutics NASDAQ:CCCC$1.32 +0.06 (+4.76%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 05/29/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$2.63 +0.08 (+3.14%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.60 -0.03 (-1.14%) As of 05/29/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
